12:00 AM
 | 
Nov 01, 2010
 |  BioCentury  |  Finance

EPS Watch

EPS Watch

Company 3Q10 EPS est 3Q10 EPS actual Outcome Growth from 3Q10 10/29 cls Wk chg % chg Mcap chg 10/29 Mcap
Amgen Inc. (NASDAQ:AMGN) $1.27 $1.36 Beat by $0.09 -9% $57.19 -$0.36 -1% -$342.7 $54,444.9
3Q10 revenues were $3.8B, unchanged from the prior year's quarter. Sales of Aranesp for anemia were $623M, down 9% from $685M in 3Q09. First-generation EPO drug Epogen epoetin alfa had 3Q10 sales of $653M, down 2% from $663M in 3Q09. Sales of neutropenia products Neupogen and Neulasta were $1.3B, up 4% from $1.16B in 3Q09. Sales of osteoporosis drug Prolia denosumab, which was launched in June, were $10M, below the Street's estimate of $32M. Amgen said the negative impact from U.S. healthcare reform on 3Q10 U.S. sales was $64M. The company reaffirmed 2010 revenue and adjusted EPS guidance at slightly below $15.1B and towards the lower end of $5.05-$5.25. The guidance includes an estimated $200M negative impact from U.S. healthcare reform.
AstraZeneca plc (LSE:AZN; NYSE:AZN) NA $1.08 NA -26% $50.46 -$1.66 -3% -$2,410.3 $73,267.9
The pharma's 3Q10 EPS figures includes a $473M charge related to ongoing product liability litigation for depression and schizophrenia drug Seroquel quetiapine. 3Q10 revenues were $7.9B, down 2% from $8.2B in 3Q09. AstraZeneca narrowed its full-year core EPS guidance to $6.50-$6.65 from $6.35-$6.65. Although sales in emerging markets grew 14% to $1.3B, U.S. sales fell 13% to $3.2B due to generic competition for Arimidex anastrozole for breast cancer, Pulmicort Respules budesonide for asthma, and Toprol-XL metoprolol for hypertension. All percentage changes assume constant currency
Bayer AG (Xetra:BAY) NA €0.95 NA...

Read the full 1654 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >